This company has been acquired
SCTL Stock Overview
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Societal CDMO, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.10 |
52 Week High | US$1.28 |
52 Week Low | US$0.26 |
Beta | 1.52 |
11 Month Change | 1.85% |
3 Month Change | 181.33% |
1 Year Change | 4.76% |
33 Year Change | -65.52% |
5 Year Change | -86.89% |
Change since IPO | -86.75% |
Recent News & Updates
Recent updates
Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%
Feb 10Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?
Feb 02Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?
Dec 23Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?
May 31Societal CDMO signs two CDMO service agreements
Oct 20Societal stock soars 20% on signing 2 manufacturing contracts
Sep 07Societal CDMO estimates to receive up to $50M on real estates' sales
Aug 16Societal CDMO, Lannett amend license and supply deal
Jul 12These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively
Apr 29Is Recro Pharma (NASDAQ:REPH) A Risky Investment?
Jan 06Recro Pharma jumps 15% on Q1 result estimates beat
May 07Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?
Feb 15Shareholder Returns
SCTL | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -3.8% | -1.0% |
1Y | 4.8% | 9.8% | 30.3% |
Return vs Industry: SCTL underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: SCTL underperformed the US Market which returned 25.9% over the past year.
Price Volatility
SCTL volatility | |
---|---|
SCTL Average Weekly Movement | 39.2% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCTL's share price has been volatile over the past 3 months.
Volatility Over Time: SCTL's weekly volatility has increased from 23% to 39% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 258 | J. Enloe | www.societalcdmo.com |
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms.
Societal CDMO, Inc. Fundamentals Summary
SCTL fundamental statistics | |
---|---|
Market cap | US$116.26m |
Earnings (TTM) | -US$13.27m |
Revenue (TTM) | US$94.64m |
1.2x
P/S Ratio-8.8x
P/E RatioIs SCTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SCTL income statement (TTM) | |
---|---|
Revenue | US$94.64m |
Cost of Revenue | US$76.50m |
Gross Profit | US$18.14m |
Other Expenses | US$31.41m |
Earnings | -US$13.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 19.17% |
Net Profit Margin | -14.03% |
Debt/Equity Ratio | 63.2% |
How did SCTL perform over the long term?
See historical performance and comparison